

Multi-Group Audit (MGA) Feedback Survey – Site Staff

OMG No: #0925-0642

Expiration Date: 05/31/2020

Multi-Group Audit (MGA) Feedback Survey-Site Staff

OMB No.: #0925-0642

Expiration Date: 05/31/2020

Collection of this information is authorized by The Public Health Service Act, Section 411 (42 USC 285a). Rights of study participants are protected by The Privacy Act of 1974. Participation is voluntary, and there are no penalties for not participating or withdrawing from the study at any time. Refusal to participate will not affect your benefits in any way. The information collected in this study will be kept private to the extent provided by law. Names and other identifiers will not appear in any report of the study. Information provided will be combined for all study participants and reported as summaries. This survey is available to clinical site staff and auditors who have participated in a Multi-Group Audit (MGA) so that we can obtain feedback on the MGA pilot and improve the MGA process.

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA #0925-0642. Do not return the completed form to this address.

Next

Multi-Group Audit (MGA) Feedback Survey-Site Staff

You recently participated in a Multi-Group Audit (MGA), wherein your organization was audited by more than one NCTN Group at the same time. Since this MGA was conducted as part of a pilot program, the Cancer Trials Support Unit (CTSU) is requesting your responses to a few brief questions so that we can evaluate the pilot and make necessary adjustments and decisions moving forward.

Please note that your responses to these questions are anonymous and have absolutely no bearing on your audit results and report. The survey results will be shared with the Clinical Trials Monitoring Branch (CTMB) to direct future program planning.

If you have any questions about MGAs or this survey, please contact Jenny Hopkins, the CTSU Audit Coordination Task Manager, at jennyhopkins@westat.com.

Prev

Next

* 1. What best describes your role? (select one)

- Investigator
- Clinical Research Coordinator/Research Nurse
- Data Manager
- Regulatory Specialist
- Quality Assurance
- Pharmacist
- Other (please describe)

2. Had you heard about MGAs before being approached about participating in one? (select one)

- Yes
- No

Prev

Next

If answer to #2 is Yes, the survey goes to question #3 as shown on the next page (page 4), if No, the survey skips to #3 as shown on page 5.

3. How did you first hear about MGAs? (select one)

- CTSU newsletter
- Group meeting
- CTSU webinar on data quality programs
- Other (please describe)

Prev

Next

* 3. What did you find most helpful/beneficial about the MGA experience? (select all that apply)

- Being able to take care of more than one Group audit at the same time
- Anticipation of fewer total audit visits over time
- A sense that having Groups audit concurrently can lead to increased standardization between the Groups
- Working with staff who you might not typically work with (e.g., site staff who focus on different study groups than you do)
- The involvement of a CTSU Audit Coordinator prior to the audit visit
- The presence of a CTSU Audit Facilitator at the audit visit
- Other, please describe additional benefits

* 4. What were the most significant challenges/dilemmas you faced as part of this experience? (select all that apply)

- Scheduling the MGA
- Knowing where to go with questions
- Amount of preparation required for a single visit
- Staff that cover multiple Groups needing to prepare for both audits at the same time
- Finding adequate space for multiple audit teams
- Coordinating multiple site staff with multiple auditors
- Large number of people in the pharmacy
- Coordinating the exit interviews
- Other, please describe other challenges

5. Do you have any suggestions about how to address the challenges you noted and/or any other ideas for general improvements to the MGAs?

Prev

Next

6. In the future, would you prefer (select one):

- An MGA at your site
- Individual Group audits on different dates

Please summarize why:

7. Do you have any other comments? Please share them here.

Prev

Done

Multi-Group Audit (MGA) Feedback Survey-Site Staff

Thank you for completing our survey!

Done